Vor Biopharma Inc. (VOR) – What Are Analysts Saying About This Stock?

Vor Biopharma Inc. (NASDAQ:VOR) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $38.00.

VOR has been the subject of several analyst reports. William Blair assumed coverage on shares of Vor Biopharma in a research report on Wednesday, October 21st. They set an “outperform” rating for the company. Wedbush lifted their price objective on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Wall Street Zen upgraded shares of Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Citigroup raised shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, October 15th. Finally, Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th.

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Vor Biopharma during the third quarter valued at $58,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Vor Biopharma by 25.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company’s stock worth $198,000 after acquiring an additional 2,171 shares during the last quarter. Cannon Global Investment Management LLC acquired a new stake in shares of Vor Biopharma during the first quarter worth $209,000. Sei Investments Co. acquired a new position in shares of Vor Biopharma in the first quarter valued at about $245,000. Finally, Independent Financial Group LLC acquired a new stake in Vor Biopharma during the 1st quarter valued at approximately $249,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Up 1.3%

Vor Biopharma stock opened at $20.91 on Friday. Vor Biopharma has a 1-year low of $6.50 and a 1-year high of $26.76. The firm’s fifty day moving average price is $20.82 and its two-hundred day moving average price is $17.31.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). Analysts anticipate that Vor Biopharma will post -2.56 earnings per share for the current fiscal year.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.